other material
confidence high
sentiment positive
materiality 0.90
SELLAS GPS hits Phase 3 REGAL primary endpoint: median OS 24.0 vs 14.7 months, HR 0.59 (p=0.035)
SELLAS Life Sciences Group, Inc.
- Median overall survival 24.0 months for galinpepimut-S (GPS) vs 14.7 months for best available treatment; 41% reduction in risk of death (HR 0.59, two-sided p=0.035).
- REGAL enrolled AML patients in second or later complete remission (CR2/CRp2+) after second-line or later salvage therapy who were ineligible for allogeneic stem cell transplant.
- Topline analysis conducted at the pre-specified 80 death events per the trial's statistical analysis plan; treatment arms balanced on prognostic factors.
- GPS generally well tolerated; treatment-related adverse events mostly grade 1/2 local injection site reactions, no new safety signals.
- SELLAS plans an FDA meeting on an accelerated filing strategy and to advance BLA preparation for GPS in the first half of 2027; secondary endpoints pending.
Featured in Daily 8-K Digest
Selected #7 for 2026-11-17.
Read digest